Alpine Immune weighing sale after takeover interest, Bloomberg says

Alpine Immune Sciences is weighing options including a potential sale after attracting takeover interest, Michelle Davis, Dinesh Nair and Manuel Baigorri of Bloomberg report, citing people with knowledge of the matter. Alpine is working with advisers to weigh a potential transaction, sources told Bloomberg. At least one larger pharmaceutical company has spoken to the company about a potential takeover, they said. Deliberations are ongoing and there’s no certainty that Alpine Immune will decide to pursue a sale, the people added. Shares of Alpine Immune Sciences are up 12%, or $4.56, to $43.50 following the report.